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TuberculosisObjective/Background: The diagnostics of latent tuberculosis infection in Poland using the
tuberculin skin test is challenging due to the obligatory Bacillus Calmette–Gue´rin
vaccinations. Interferon-gamma release assays are still very rarely used for diagnostics.
We compared the tuberculin skin test and the QuantiFERON-TB Gold In-Tube test to eval-
uate the degree of latent tuberculosis infection in at-risk groups for tuberculosis (homeless,
close contacts, periodic contacts, nursing-home attendees) and in healthy individuals.
Methods: QuantiFERON-TB Gold In-Tube tests were carried out on 785 individuals from the
homeless (n = 150), close contacts (n = 171), periodic contacts (n = 163), nursing-home atten-
dees (n = 152), and healthy individuals (n = 149). The tuberculin skin test was performed on
129, 156, 147, 148, and 121participants, respectively.Weevaluated the (a) correlationbetween
serum concentrations of interferon gamma and the tuberculin-skin-test induration diame-
ter; (b) between the number of QuantiFERON-TB Gold In-Tube-positive results and the
tuberculin-skin-test diameter in the studied groups; and (c) agreement between both tests
and the kappa coefficient using the tuberculin-skin-test diameters of 5, 10, and 15 mm.
Results: Larger tuberculin-skin-test induration diameters were associated with elevated
serum concentrations of interferon gamma. We found a positive correlation between the
number of positive QuantiFERON-TB Gold In-Tube screening results and the tuberculin-
skin-test induration diameter. The agreement between QuantiFERON-TB Gold In-Tube and
tuberculin-skin-test screening results improvedwith increasing tuberculin-skin-test indura-
tion diameter.
Conclusion: Based on measures of tuberculin-skin-test induration diameter alone, it is diffi-
cult to diagnose latent tuberculosis infection with certainty. The agreement of the
QuantiFERON-TB Gold In-Tube test increases with the tuberculin-skin-test diameter.
Tuberculin-skin-test diameters larger than 15 mm are more likely to be associated with
active infection.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.
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Introduction
It is estimated that at least 32% of the world’s population
(approximately 1.8 billion) is infected with Mycobacterium
tuberculosis; the majority have asymptomatic, latent tubercu-
losis infection (LTBI). In countries with low and medium
incidence of tuberculosis, the treatment of LTBI serves to halt
the progression of this infection into the active form of the
disease. This is particularly important for at-risk individuals,
such as those recently infected, in close contact with a
contagious patient, infected with human immunodeficiency
virus (HIV), and people with previously untreated pulmonary
fibrosis [1].
The tuberculin skin test (TST) is the standard method used
to determine whether an individual is infected with
M. tuberculosis. However, instances of tuberculin allergy can
occur after a natural infection with the mycobacteria, or as
a result of the Bacillus Calmette–Gue´rin (BCG) vaccine admin-
istration. For this reason, in countries (including Poland)
where vaccinations, especially repeated ones, so-called revac-
cinations, were mandatory, the precise evaluation of the rate
of mycobacterium infection using the tuberculin test is prac-
tically impossible. The immunological basis of the tuberculin
test is the presence of a subset of T lymphocytes, known as
central memory cells, which, in the event of repeated antigen
presentation using tuberculin (a mixture of approximately
200 mycobacterial antigens), quickly gather and replicate to
control the pathogen. The tuberculin test is not particularly
specific, as the purified protein derivative is a mixture of pro-
teins, whose antigen determinants are present in most spe-
cies of mycobacteria, including the BCG vaccine. With BCG
vaccinated patients and those infected with atypical
mycobacteria, the so-called environmental mycobacteria,
the TST result may yield a false positive [1–3]. In Poland, the
National Program for Combating Tuberculosis recommends
an induration diameter of at least 10 mm as positive tubercu-
losis skin test for the entire population (with the exception of
HIV-positive patients, for whom a reaction of at least 5 mm is
considered to be positive) [1–4].
Within the last few years, new methods have been
developed to detect latent M. tuberculosis infection, such as
QuantiFERON-TB Gold (Cellestis Ltd., Carnegie, Australia,
now part of Qiagen) and T-SPOT.TB (Oxford Immunotec,
Abingdon, Great Britain), which are highly specific and sensi-
tive for detectingM. tuberculosis infection. These tests are typ-
ically peptide-based interferon-gamma (IFN-c) assays, which
measure the amount of serum IFN-c released by specific T
lymphocytes in response to antigen presentation by M. tuber-
culosis and a small number of other species of mycobacteria
(Mycobacterium kansasii, Mycobacterium szulgai, and Mycobac-
terium microti). The diagnostic antigenic peptides used to
induce IFN-c release are early secretory antigenic target-6
(ESAT-6) and culture filtrate protein-10 (CFP-10), and the most
recent version of the QuantiFERON-TB Gold In-Tube (QFT-GIT)
test also includes the M. tuberculosis-specific antigen, TB7.7
[3–13]. These antigens are not present in the BCG strain
bacteria, which increase the diagnostic value of these tests.
Most investigators have concluded that interferon-gamma
release assays (IGRAs) have high specificity (around 62–100%,greater than TST), since these assays are not influenced by a
mycobacteria. The tests are also highly sensitive; for example,
the sensitivity of the enzyme-linked immunospot varies
between 83% and 97%, and was higher than the enzyme-lin
ked-immunosorbent-assay method (70–89%) [3–13]. Most
studies have reported concordance at 60–90% for TST and
IGRA screening tests [3,10–13]. Discordant results, TST posi-
tive/IGRA negative, are most likely associated with prior
BCG vaccinations, as well as immunization with nontubercu-
losis environmental mycobacteria. However, it is also possible
that IGRA has reduced sensitivity in specific clinical situa-
tions, as well as the limited ability to detect the immune
response during certain stages of infection, for example, a
recent infection that is quickly subject to spontaneous remis-
sion or responded quickly to treatment [3]. It is possible that
discordant results (TST positive/IGRA negative) are associated
with short incubation time of the specific mycobacterial anti-
gens. In support of this, several studies have demonstrated
that, when the incubation time using the QuantiFERON test
was extended for several days, the initially negative test
result returned a positive result [14]. The second type of dis-
cordant result, TST negative/IGRA positive, is more difficult
to understand. It may be necessary to change the cutoff
points applied so far, in order to increase the sensitivity of
IGRA tests. It is also probable that the IGRA tests, as stated
previously, detect recent mycobacterial infections, due to
the effector T cells. (The TST screen remains negative, as cen-
tral memory cells, which take part in this reaction, are not yet
stimulated and do not respond with an IFN-c release [14].)
Additionally, it must be taken into consideration that, in
countries with a high tuberculosis incidence, there are many
factors that modulate the immunological balance of Th1/Th2,
for example, malnutrition, environmental mycobacteriosis,
leprosy, verminous diseases, and tropical infections [7].
In this study, we compared the QFT-GIT and TST screening
methods used to detect M. tuberculosis in at-risk groups. The
at-risk groups were the homeless, close contacts, periodic
contacts, and care homeworkers, and were compared to
healthy people selected at random. We analyzed the follow-
ing: (a) the relationship between serum concentrations of
IFN-c and the TST induration diameters; (b) the relationship
between the number of QFT-GIT-positive results and the
TST induration diameter; and (c) the concordance between
QFT-GIT screening results and TST induration diameter at
thresholds of 5, 10, and 15 mm.Materials and methods
Between July 2007 and September 2009, M. tuberculosis infec-
tion was assessed using the QFT-GIT test in four at-risk
groups: 145 homeless people, 171 close contacts, 163 periodic
contacts, and 152 nursing-home attendees and personnel. We
tested 149 randomly selected healthy inhabitants of Krako´w
to serve as our control group. In total, 785 people were tested
(Table 1). The tuberculin-reaction test was carried out for 129,
156, 147, 148, and 121 individuals from the aforementioned
groups, respectively.
Table 1 – Group characteristics.
Group 1:
homeless
Group 2: close
contacts
Group 3:
periodic
contacts
Group 4:
nursing-home
attendees
Group 5:
healthy
Total 150 171 163 152 149
Age: median (lower–upper) 50 (20–81) 49.5 (1–96) 45 (22–67) 47 (23–85) 44 (16–81)
Males 114 80 29 71 49
Females 30 91 134 81 100
Table 2 – Spearman’s rank correlation coefficients between
serum interferon-gamma levels and the tuberculin-skin-
test induration diameter.
Group Spearman’s coefficient p
Homeless .55 <.001
Close contacts .31 <.001
Periodic contacts .41 <.001
Nursing-home attendees .41 <.001
Healthy .29 <.001
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Committee of the Jagiellonian University (agreement number
KBET/66/B/2008; September 25, 2008). During the period July
2007 to September 2008, the participants were examined
within the preventive program led by the authors and funded
by the Municipal Office of Krako´w. The implementation of the
program did not require the approval of the local bioethics
committee. After the decision to initiate the clinical study
from 2008, the approval was received from the Bioethics Com-
mittee of the Jagiellonian University. The study was contin-
ued with the participation of people who provided informed
consent, including the use of the results of tests obtained in
the years 2007–2008. The participants provided a written
informed consent for their results to be used in the clinical
study and for enrollment in the study groups.
All of the people tested completed a questionnaire spe-
cially designed for this study, which details any current and
prior illnesses, addictions/habits, and social status. In addi-
tion to a physical examination, the scar after a BCG vaccina-
tion was assessed for all the study participants.
All of the test participants had TST applied by administer-
ing 0.1 mL of tuberculin (2 cc purified protein derivative RT-23)
intradermally into the ventral aspect of the forearm by an
experienced nurse. The induration diameter who measured
assessed after 72 h later, a diameter of at least 10 mm was
considered a positive test result. We also used the QFT-GIT
test (Cellestis Ltd.) as the IGRA test of choice.
On the first day of the TST, 1 mL of blood was sampled
from each test participant, and divided between three test
tubes: the first coated with ESAT-6, CFP-10, and TB7.7 anti-
gens; the second coated with a mitogen, which consisted of
phytohemagglutinin A (positive control); and the third, which
constituted a negative control (a buffered solution of salt with
0.1% thimerosal).
Statistical analysis
The relationship between TST induration diameter and
plasma IFN-c concentration was evaluated using a Spear-
man’s correlation coefficient. This value was reported, along
with its relevance, and dispersion charts indicating the
threshold values for the given tests.
A chi-square test of independencewas performed between
the QFT-GIT results and the TST diameter.
The concordance of the tests was carried out by calculat-
ing the kappa coefficient value (j) with a 95% confidence
interval. Data are presented in the form of tables of contin-
gency, additionally providing p for the independence test
(chi-square test).Two-tailed tests were used throughout this study, and a
critical value of p < .05 was used to determine statistical
significance.
Results
Relationship between serum concentrations of IFN-c and
induration diameter in the TST
The relationship, assessed using Spearman’s rank correlation
coefficient, between IFN-c concentrations and TST induration
diameters in the tested groups was between .3 and .6, which
indicated a moderate correlation (Table 2). This is in line with
the expected outcome (i.e., the larger induration diameters
resulted in higher greater serum IFN-c concentrations).
QFT-GIT positive results are associated with TST induration
diameter
We next examined whether the correlations between serum
IFN-c concentrations and TST induction diameter hold true
when different diameters were examined at different
thresholds. We grouped the induration diameters into the
following groups: (a) <4 mm, (b) 5–9 mm, (c) 10–14 mm, and
(d) P15 mm.
We evaluated the number of positive results based on the
QFT-GIT test screen in relation to the TST induration diameter
for all the at-risk groups and healthy individuals, and the
number of positive TST results in these ranges (Figs. 1–5). In
all the groups, greater numbers of QFT-GIT-positive results
were found with increasing TST induration diameter.
The chi-square test independence test for all groups
revealed statistically significant differences in the number of
positive and negative QFT-GIF results depending on the TST
diameter (in the healthy group p = .02, in at-risk groups
p < .001).
Fig. 1 – Distribution of positive QuantiFERON-TB test results
grouped according to tuberculin-skin-test induration
diameter in homeless people. QFT-GIT = QuantiFERON-TB
Gold In-Tube; TST = tuberculin skin test.
Fig. 2 – Distribution of positive QuantiFERON-TB test results
grouped according to tuberculin-skin-test induration
diameter for the close-contact individuals. QFT-
GIT = QuantiFERON-TB Gold In-Tube; TST = tuberculin skin
test.
Fig. 3 – Distribution of positive QuantiFERON-TB test results
grouped according to tuberculin-skin-test induration
diameter for periodic contacts. QFT-GIT = QuantiFERON-TB
Gold In-Tube; TST = tuberculin skin test.
Fig. 4 – Distribution of positive QuantiFERON-TB test results
grouped according to tuberculin-skin-test induration
diameter for nursing-home attendees. QFT-
GIT = QuantiFERON-TB Gold In-Tube; TST = tuberculin skin
test.
Fig. 5 – Distribution of positive QuantiFERON-TB test results
grouped according to tuberculin-skin-test induration
diameter for healthy individuals. QFT-GIT = QuantiFERON-
TB Gold In-Tube; TST = tuberculin skin test.
30 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 2 7 –3 3Agreement of QFT-GIT and TST
We initially considered a positive TST value to be diameters
10 mm or greater, but also considered values above 15 mm.
We compared the number positive results based on the
QFT-GIT screen with positive from the TST using the two
diameter measures (P10 mm and P15 mm). Fig. 6 shows
the percentage distribution of positive QFT-GIT test results
and positive TST results using both induration diameters.
The percentage frequency of positive TST results was
almost twice as large when a positive result was considered
to be an induration diameter equal or larger than 10 mm.
When it was assumed that a positive TST result was a diam-
eter equal or larger than 15 mm, the frequency of positive
results was similar to that of the QFT-GIT test.
Based on the analyses of the concordant results of
these tests, we observed TST positive/QFT-GIT positive and
TST negative/QFT-GIT negative. We also identified two
discordant results: TST positive/QFT-GIT negative and TST
Fig. 6 – Mycobacterium tuberculosis infection based on
QuantiFERON-TB test results and tuberculin reaction
(P10 mm and P15 mm) in at-risk and healthy individuals.
QFT = QuantiFERON-TB; TST = tuberculin skin test.
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results were TST positive/QFT-GIT negative, which may be
accounted for by the influence of multiple BCG vaccinations
on the TST result. Subsequently, the agreement between
QFT-GIT and TST screens was assessed taking TST induration
values as positive at thresholds of 5, 10, and 15 mm (Table 3).
For the majority of groups, we found the agreement
between QFT-GIT and TST screening results (j coefficients)
improved when larger TST induration diameters were used.
In no instance did j coefficient values exceed .6.
Discussion
Investigations of latent M. tuberculosis infection in at-risk
groups aim to provide quick identification of individuals with
an active form of the disease. This is particularly important
for the management of tuberculosis in countries with a rela-
tively low incidence rate, which may soon also include
Poland. Such action is intended to prevent further transmis-
sion of tuberculosis by quickly diagnosing and treating its
active form, while the detection of LTBI in people who come
in contact with tuberculosis patients makes it obligatory for
doctors to carry out regular control examinations andTable 3 – Agreement between QuantiFERON-TB Gold In-Tube an
threshold.
Risk groups
Homeless Correspondence (%)
Kappa
Close contacts Correspondence (%)
Kappa
Periodic contacts Correspondence (%)
Kappa
Nursing-home attendees Correspondence (%)
Kappa
Healthy Correspondence (%)
Kappa
TST = tuberculin skin test.consider the incorporation of chemoprophylaxis treatment.
The incidence of tuberculosis among people infected with
M. tuberculosis is highest shortly following infection, and
may reach 30–40% of infected among small children and
about 2% among primary schoolchildren [15]. As stated previ-
ously, in Poland, chemoprophylaxis treatment currently only
includes children and adolescents, and HIV-positive patients.
The relatively high incidence of tuberculosis in Poland
(18.6/100,000), in 2013, did not enable the effective treatment
of latent tuberculosis in a larger group of people. This was
complicated by the difficulty in diagnosing patients due to
the ineffectiveness of TSTs, caused by repeated BCG vaccina-
tions. Until recently, a BCG vaccination calendar was in effect
in Poland. As well as vaccinations of newborns, there were
obligatory booster vaccinations in the 1st, 6th, 12th, and
18th years of life. After a single administration of the BCG vac-
cine, the immunization is maintained for 10–15 years; after
this time, if revaccination does not take place, all the positive
tuberculin reactions could be treated as signs of infection
(with the exception of the minimal influence of environmen-
tal mycobacteria on the tuberculin reaction in Poland). Unfor-
tunately, numerous revaccinations after the infancy period
result in the maintenance of a particularly high tuberculin
response for many years [16,17]; as a result, there has so far
been no sure way to differentiate a postvaccination reaction
from a post-infectious one. Currently, the IGRA tests (includ-
ing the QFT-GIT test used in this study), whose specificity
reaches nearly 98–100%, fulfills the primary role of determin-
ing the degree of M. tuberculosis infection [18]. These assays
are especially diagnostically significant in those countries
(including Poland) where numerous BCG revaccinations are
or were in effect. Unfortunately, we are currently unable to
determine whether a positive IGRA test result is due to the
presence of living, ‘‘dormant” bacteria in the organism, or
only due to the activation of central memory cells, which
were in contact with mycobacteria in the past. This also
applies to the tuberculin reaction as a diagnostic test of LTBI
[19].
In this study, two types of concordant results of these tests
were identified: TST positive with QFT-GIT positive and TST
negative with QFT-GIT negative, as well as two discordantd tuberculin-skin-test results at the 10-mm and 15-mm
TST 5 mm TST 10 mm TST 15 mm
58.7 60.7 75.4
.26 .34 .45
55.8 73.0 73.4
.20 .29 .32
53.7 75.0 76.1
.19 .30 .40
64.0 78.8 79.0
.29 .36 .45
55.8 60.9 70.0
.20 .24 .23
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with QFT-GIT positive. Most instances of disagreement were
QFT-GIT-negative with TST-positive results. This appears to
be associated primarily with the influence of multiple BCG
vaccinations on the TST result. In certain groups, increased
tuberculin-reaction induration diameter showed good agree-
ment with the QFT-GIT screen, based on the j coefficients.
Our findings are broadly in line with those reported by other
investigators. Diel et al. [20] observed concordance for both
tests at a level of 63.8–69.2% (j = .2–.28) in a group of patients
with BCG vaccinations, and 89.5–90.7% (j = .58–.62) in the
group of unvaccinated patients. Similarly, Ferrara et al. [21]
observed an agreement of 41% (j = .09) in the vaccinated
group, and 80% (j = .56) in the unvaccinated group. In a large
cohort study, conducted by Arend et al. [22], an agreement of
75.4% (j = .33) was reported when using a cutoff point of 10-
mmTSTinduration diameter in the unvaccinated group. Using
TSTof at least 15 mm, the agreement reached 86.5% (j = .49). It
is commonly accepted that the larger the TST induration
diameter, the more likely it is for infection to occur, and is
commonly accepted to be 15 mm or more. Such an induration
diameter is considered to be an infectious reaction, rather
than a postvaccination response [16]. In an earlier study, we
[23] and Kus´ et al. [24] assessed the degree of M. tuberculosis
infection among the Polish population. The QFT-GIT test was
more useful for diagnosing M. tuberculosis infection [23,24],
and found to have greater predictive accuracy for assessing
the development of an active form of tuberculosis [25].
In the present study, we compared TST and QFT-GIT
screening methods for the diagnosis of M. tuberculosis infec-
tion in at-risk groups and in healthy individuals. Consistent
with the findings of others, and in line with the expected out-
come, we found that TST induration diameters correlated
with serum IFN-c concentrations, analyzed using the QFT-
GIT test. This is to be expected, since the same cytokines par-
ticipate in both types of reactions; in the case of QFT-GIT,
cytokines are released by T cells into the serum following
stimulation by specific mycobacterial antigens, while in the
TST, cytokines are released at the tubulin injection site.
Spearman’s rank-correlation-coefficient values .3–.6 indicate
low (homeless group) or medium (other groups) correlation
between IFN-c concentrations and TST induration diameter.
These findings suggest that patients with a large TST indura-
tion diameter have higher serum concentrations of IFN-c.
Additionally, based on the positive correlation between the
number of positive QFT-GIT test results and the tuberculin-
reaction induration diameter, it follows that the probability
of a positive QFT-GIT result for a tested patient rises with
increasing TST diameter. However, our results do not allow
us to determine whether high TST values (e.g., over 15-mm
induration diameter) will always yield QFT-GIT-positive
results for a given patient. This is because QFT-GIT-positive
test results (as well as high levels of IFN-c) can be observed
in patients with a TST diameter of 0 mm, as well as 20 mm.
Therefore, we have shown that a positive TST result (over
15 mm) indicates a high probability of M. tuberculosis
infection, while at the same time a negative result should
not automatically rule out infection.
The results of this study demonstrate the rising diagnostic
value of TST induration diameter in vaccinated patients. Itshould be noted, however, that the observed results and j
coefficients never reached a high agreement level in any of
the groups included in this study. Our data indicate that
TST induration diameters of at least 15 mm are suggestive,
but not necessarily indicative, of M. tuberculosis infection.
Particular care must be taken when adopting specific
TST induration-diameter thresholds used to indicate
M. tuberculosis infection.Conflicts of interest
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